Breaking News

Financial Report: Alkermes 2Q12

Elan portfolio makes contribution

Alkermes 2Q12 

2Q Revenues: $72.0 million (+46%)

2Q Loss: $22.3 million (loss of $7.7 million 2Q11)

Comments: Manufacturing and royalty revenues from Risperdal Consta were $44.3 million in the quarter, up 5%. Vivitrol sales were $9.9 million, compared to $6.5 million, up 52%. Alkermes completed the merger with Elan Drug Technologies (EDT) on Sept. 16, 2011. The EDT portfolio contributed $9.1 million to revenues in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters